Report from Canada’s Drug Agency says Wegovy cuts risk of heart attack, stroke or cardiovascular death by 20 per cent

If federal, provincial and territorial governments follow the CDA’s advice, Wegovy would be the first prescription weight loss drug to be covered by public insurance plans.

Provincial governments should pay for the weight-loss drug Wegovy for people who are overweight and have survived a heart attack or stroke, according to a new report from the organization that advises Canadian public drug plans on which new medications to cover.

Canada’s Drug Agency, which released the draft recommendation on Thursday, said taxpayer-funded drug plans should reimburse Wegovy for people with a body mass index of 27 or higher and pre-existing cardiovascular disease because a clinical trial found the once-weekly injection cut their risk of another heart attack, stroke or cardiovascular death by 20 per cent.

From The Globe and Mail via this RSS feed